Literature DB >> 8843035

Selected P2 purinoceptor modulators prevent glutamate-evoked cytotoxicity in cultured cerebellar granule neurons.

C Volonté1, D Merlo.   

Abstract

Primary cultures of granule neurons derived from cerebella of postnatal rats are endowed with Glu receptors. Glu receptor agonists exert a trophic influence on differentiating granule cells but, with maturation, the cells become vulnerable to excitatory amino acids. Here we show that the P2 purinoceptor antagonist basilen blue abolishes in rat cerebellar granule neurons the cytotoxic action of glutamate with an IC50 in the 10-20 microM range. Within the same concentrations, basilen blue inhibits binding of [3H] ATP to cerebellar granule cells, glutamate-evoked release (but not uptake) of [3H] D-aspartate and Ca2+ uptake. Furthermore, the extracellular phosphorylation of a major 45-kDa endogenous ecto-protein substrate of cerebellar granule neurons is inhibited with an IC50 of about 1 microM. Similar effects are elicited by 5-adenylylimidodiphosphate, a P2 purinoceptor agonist, when supplied to the neurons for 8 days previously to the addition of glutamate. Our data point to the use of P2 purinoceptor modulators as novel elements for understanding and controlling glutamate-mediated excitatory neurotoxicity and neurotransmission. We suggest a possible involvement of P2 purinoceptors in these actions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843035     DOI: 10.1002/(SICI)1097-4547(19960715)45:2<183::AID-JNR10>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  9 in total

1.  Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices.

Authors:  Elisabetta Coppi; Anna Maria Pugliese; Holger Stephan; Christa E Müller; Felicita Pedata
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

2.  Block of P2X7 receptors could partly reverse the delayed neuronal death in area CA1 of the hippocampus after transient global cerebral ischemia.

Authors:  Qiang Yu; Zhili Guo; Xiaofeng Liu; Qing Ouyang; Cheng He; Geoffrey Burnstock; Hongbin Yuan; Zhenghua Xiang
Journal:  Purinergic Signal       Date:  2013-07-23       Impact factor: 3.765

3.  Amyloid-beta induces a caspase-mediated cleavage of P2X4 to promote purinotoxicity.

Authors:  R Varma; Y Chai; J Troncoso; J Gu; H Xing; S S Stojilkovic; M P Mattson; N J Haughey
Journal:  Neuromolecular Med       Date:  2009-06-27       Impact factor: 3.843

Review 4.  Ion channels as drug targets in central nervous system disorders.

Authors:  A M Waszkielewicz; A Gunia; N Szkaradek; K Słoczyńska; S Krupińska; H Marona
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 5.  P2 receptors and neuronal injury.

Authors:  Heike Franke; Ute Krügel; Peter Illes
Journal:  Pflugers Arch       Date:  2006-04-28       Impact factor: 3.657

6.  Regional expression of P2Y(4) receptors in the rat central nervous system.

Authors:  Xianmin Song; Wei Guo; Qiang Yu; Xiaofeng Liu; Zhenghua Xiang; Cheng He; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2011-07-19       Impact factor: 3.765

7.  Increased resistance of glioma cell lines to extracellular ATP cytotoxicity.

Authors:  Fernanda B Morrone; Ana Paula Horn; Joseli Stella; Fernando Spiller; João J F Sarkis; Christianne G Salbego; Guido Lenz; Ana Maria O Battastini
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

8.  Enhanced expression of P2X4 purinoceptors in pyramidal neurons of the rat hippocampal CA1 region may be involved ischemia-reperfusion injury.

Authors:  Zhenghua Xiang; Xin Jiang; Rihui Ji; Hongbin Yuan
Journal:  Purinergic Signal       Date:  2021-05-09       Impact factor: 3.765

9.  The role of ATP and adenosine in the brain under normoxic and ischemic conditions.

Authors:  F Pedata; A Melani; A M Pugliese; E Coppi; S Cipriani; C Traini
Journal:  Purinergic Signal       Date:  2007-10-11       Impact factor: 3.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.